HAYWARD, Calif.–(BUSINESS WIRE)–#antibodies—Aarvik Therapeutics announced the recent publication by Sachdev Sidhu, Ph.D., Co-founder of Aarvik Therapeutics, and his colleagues of a study validating the novel tetravalent antibody platform that forms a core component of innovation at Aarvik. This study by Miersch et al. uses modular design principles to combine neutralizing antibodies against two independent epitopes of the SARS-COV-2 spike protein into a single bi-paratopic, tetravalent antibody. The tetravalent antibody behaves like conventional IgGs on yield, purity, stability, and solubility but demonstrates potency and breadth of coverage that far exceed conventional bivalent IgGs. This tetravalent antibody platform offers enormous potential not just in infectious disease but also in oncology and other therapeutic areas.
The proprietary tetravalent antibody platform enables the efficient creation of antibodies in a high-throughput manner. Aarvik utilizes this platform to rapidly design and generate tetravalent antibodies against a variety of oncology targets. These antibodies can elegantly combine multiple independent antibody paratopes to potentially improve the clinical activity of various therapeutic modalities, including antibody drug conjugates (ADCs), which currently use conventional IgG antibodies.
“We are extremely excited to see the expanding proof of concept for this powerful tetravalent antibody platform,” said Jagath Reddy Junutula, Ph.D., Co-founder, President, and CEO of Aarvik Therapeutics. “Dr. Sidhu is a world-renowned leader in protein engineering, and Aarvik substantially benefits from the deep expertise possessed by him and his team in engineering novel antibodies.”
The study’s principal investigator, Sachdev Sidhu, Ph.D., added, “We are excited to work with the Aarvik team and to continue exploration of this modular platform and its potential to generate functional antibodies with previously unrealized biological and therapeutic properties.”
About Aarvik Therapeutics
Aarvik Therapeutics combines a unique, proprietary modular platform with multiple target mechanisms and therapeutic modalities to develop novel molecules with an improved therapeutic index for oncology and other diseases. Backed by extensive scientific, research, drug development and business expertise from its founders, team members, SAB and Board, Aarvik Therapeutics is applying its vision and passion to create transformational benefit for patients with cancer and other diseases.
For additional information, visit www.aarviktx.com.
Contacts
Pradeep Fernandes
contact@aarviktx.com
